“We are now finishing the“ preclinic ”and after the New Year holidays we intend to begin a clinical trial of a drug based on monoclonal antibodies for the treatment of those already ill with COVID-19,” he said in a comment to Interfax.
According to the head of the center, first of all, the medicine will be intended for the treatment of people from risk groups, which include pregnant women, diabetics and people with obesity.
In clinical trials, scientists will find out at what time of the disease the drug is most effective.
“I think that not only in the early stages, it is possible that on the fourth or sixth day too.
But this task will already be for clinical trials - to see until what day it makes sense to introduce them, ”explained Gunzburg.
Earlier, he spoke about the development in Russia of a drug that suppresses the multiplication of coronavirus.